Abstract
Acquired Immunodeficiency Syndrome (AIDS) was discovered 30 years ago and was followed by the identification and characterization of its causative agent, Human Immunodeficiency Virus (HIV). Increasing spread of retroviral infections has impelled science to understand the evolution of retroviruses from primates to humans. In the course of evolution, host cells have developed intracellular proteins to counteract the transforming viral defence system. Such inhibitory endogenous intracellular proteins are known as restriction factors. Tripartite motif protein isoform 5 alpha (TRIM5α), Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like (APOBEC), and Tetherin proteins are few important restriction factors that have been extensively studied. Several evidences have conveyed information regarding specific adaptations occurring in HIV-1 and its relatives to inhibit these host defenses; making the study more interesting. The characteristic potential of restriction factors to restrict the replication of retroviruses was enticing when studies were found that HIV-1 virus cannot infect nonhuman primate species. This review emphasizes on TRIM5α as a restriction factor and its significance in the evolution of retroviruses. It also accentuates the role of polymorphism within the regions of TRIM5α in both human and primate species that eventually affect the cross-species transmission of immunodeficiency viruses.
Keywords: Acquired immunodeficiency syndrome, human immunodeficiency virus, restriction factor, transmission, TRIM5α.
Current HIV Research
Title:Role of Trim5α in the Suppression of Cross-Species Transmission and its Defence Against Human Immunodeficiency Virus
Volume: 11 Issue: 8
Author(s): Madhuri P. Puvvada and Snehal S. Patel
Affiliation:
Keywords: Acquired immunodeficiency syndrome, human immunodeficiency virus, restriction factor, transmission, TRIM5α.
Abstract: Acquired Immunodeficiency Syndrome (AIDS) was discovered 30 years ago and was followed by the identification and characterization of its causative agent, Human Immunodeficiency Virus (HIV). Increasing spread of retroviral infections has impelled science to understand the evolution of retroviruses from primates to humans. In the course of evolution, host cells have developed intracellular proteins to counteract the transforming viral defence system. Such inhibitory endogenous intracellular proteins are known as restriction factors. Tripartite motif protein isoform 5 alpha (TRIM5α), Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like (APOBEC), and Tetherin proteins are few important restriction factors that have been extensively studied. Several evidences have conveyed information regarding specific adaptations occurring in HIV-1 and its relatives to inhibit these host defenses; making the study more interesting. The characteristic potential of restriction factors to restrict the replication of retroviruses was enticing when studies were found that HIV-1 virus cannot infect nonhuman primate species. This review emphasizes on TRIM5α as a restriction factor and its significance in the evolution of retroviruses. It also accentuates the role of polymorphism within the regions of TRIM5α in both human and primate species that eventually affect the cross-species transmission of immunodeficiency viruses.
Export Options
About this article
Cite this article as:
Puvvada P. Madhuri and Patel S. Snehal, Role of Trim5α in the Suppression of Cross-Species Transmission and its Defence Against Human Immunodeficiency Virus, Current HIV Research 2013; 11 (8) . https://dx.doi.org/10.2174/1570162X12666140306124543
DOI https://dx.doi.org/10.2174/1570162X12666140306124543 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
Management of HIV: Management of HIV: old challenges and new needs
The aim of this thematic issue is to provide the most recent updates regarding the effective management of HIV infection. Antiretroviral therapy (ART) has significantly decreased HIV-related mortality, leading to an enhancement in the quality of life and life expectancy for people living with HIV (PLWH). Despite the numerous advancements ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
B Cell Modulation Strategies in Autoimmunity: The SLE Example
Current Pharmaceutical Design Hybrid Molecules Synergistically Acting Against Protein Aggregation Diseases
Current Topics in Medicinal Chemistry Mitochondrial Proteases as Emerging Pharmacological Targets
Current Pharmaceutical Design Current Perspectives of Healthy Mitochondrial Function for Healthy Neurons
Current Drug Targets MicroRNAs Determining Inflammation as Novel Biomarkers and Potential Therapeutic Targets
Current Medicinal Chemistry Opioids and the Blood-Brain Barrier: A Dynamic Interaction with Consequences on Drug Disposition in Brain
Current Neuropharmacology Mesenchymal Stem/Stromal Cells: A New "Cells as Drugs" Paradigm. Efficacy and Critical Aspects in Cell Therapy
Current Pharmaceutical Design Current Concepts for Optimizing the Therapeutic Index of Glucocorticoid Receptor Ligands for Oral and Inhalative Use: Basic Considerations and Clinical Reality
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Autoimmune Diabetes Mellitus: The Importance of Autoantibodies for Disease Prediction and Diagnostic Support
Current Immunology Reviews (Discontinued) Parasite Prolyl Oligopeptidases and the Challenge of Designing Chemotherapeuticals for Chagas Disease, Leishmaniasis and African Trypanosomiasis
Current Medicinal Chemistry Editorial [Hot topic: Molecular Ophthalmology (Guest Editor: David W. Li)]
Current Molecular Medicine Treatment Strategy Issues for Chronic HIV-1 Infection in Adults: The Dilemma of Life-long Antiretroviral Treatment
Current Medicinal Chemistry - Anti-Infective Agents Mycoplasma pneumoniae Attachment Proteins and Toxins as Mediators in Disease Production
Current Pediatric Reviews Protease Inhibitors with Antileishmanial Activity
Current Enzyme Inhibition dUTPase in Human Neoplastic Cells as a Potential Target for Therapeutic Intervention
Current Protein & Peptide Science Dietary Phytoestrogens: Neuroprotective Role in Parkinson’s Disease
Current Neurovascular Research Outfielders Playing in the Infield: Functions of Aging-Associated "Nuclear" Proteins in the Mitochondria
Current Molecular Medicine Targeted Protein Degradation: An Emerging Therapeutic Strategy in Cancer
Anti-Cancer Agents in Medicinal Chemistry Sepsis, Coagulation and Anticoagulants
Endocrine, Metabolic & Immune Disorders - Drug Targets The Regulation of Neuroimmune-Endocrine Interactions: Mechanisms,Molecular Pathways Unraveled and the Pivotal Role of Cytokines – A Unsung Putative Bidirectional Interdependence between the Immune and Neuroendocrine Interfaces
Current Immunology Reviews (Discontinued)